Conventus Orthopaedics said today that it named Rick Epstein as its new chief executive officer and board member.
The Minneapolis-based company said that Epstein has more than 30 years in executive leadership roles, having previously served as chief executive officer for Omni Life Sciences.
“Rick has a track record of accelerating businesses through a focus on customer needs, meaningful product introductions and commercial success. We are excited to have Rick lead Conventus to its next chapter of growth as we strive to change the practice of medicine,” board chair Richard Mott said in a prepared statement.
“I am excited to join the Conventus team and lead the company through portfolio expansion and commercial growth. The Conventus CAGE technology is an innovative platform that is already improving patient outcomes in upper extremity fracture care. Our unique 3- dimensional, intramedullary solution provides a platform for expansion of differentiated products that address significant clinical unmet needs and enhance treatment options,” Epstein said in a press release.
CeQur said today that it appointed former Kyphon exec Bradley Paddock as its new chief executive officer, effective immediately, with current CEO Robert Farra moving to take up the role of chief technology officer.
Prior to joining the Marlborough, Mass.-based company, Paddock lead Kyphon to sales of up to $600 million over his eight years with the company. Paddock has also held positions with Stryker, Bausch + Lomb and Medtronic.
“The board unanimously voted in favor of Brad’s appointment and we are thrilled to welcome someone of such caliber to the team. The sales increase he drove at Kyphon resulted in an acquisition by Medtronic for $4.2 billion. We believe that this accomplishment, in addition to his impressive history developing commercial organizations, will ensure that CeQur is best placed for rapid development ahead of our launch of the PAQ MEAL insulin delivery device in early 2020. Bob Farra successfully led CeQur through several significant pre-commercial hurdles, including the development of our commercial-ready wearable platform, and helped the company acquire Calibra. We are grateful and honored that he will continue leading the charge on CeQur’s novel platform technology as our new chief technology officer,” exec chair Eric Milledge said in a prepared statement.
“I was drawn to CeQur because it has all the hallmarks of a successful, commercial medical device company, including novel technology that addresses a large, unmet patient need, a stellar leadership team and strong financial backing. I look forward to working with the team to bring PAQ MEAL and PAQ TOTAL to the market,” Paddock said in a prepared statement.
Outset Medical said today that it appointed former Illumina exec Rebecca Chambers as its new chief financial officer.
During her time at Illumina, Chambers managed numerous financial functions including treasury, clinical financial planning and analysis and investor relations, San Jose, Calif.-based Outset Medical said.
Prior to joining Illumina, Chambers also held positions with Myriad Genetics, Life Technologies, Bank of America Merrill Lynch and Millennium Pharmaceuticals, the company said.
“Rebecca’s deep capital markets expertise and growth-company track record is ideally suited to our stage of commercial expansion. We recognized in Rebecca a best-in-class ability to build a strong financial foundation and effective, transparent relationships with the investment community. We are thrilled to welcome her to the leadership team,” CEO Leslie Trigg said in a press release.
“I am honored to be a part of Outset at this time in its growth trajectory. It is a rare opportunity to join a team passionate about transforming a stagnant, but rapidly growing market with a huge unmet patient need. The Tablo Hemodialysis System has the potential to fundamentally change the way dialysis is delivered and improve the lives of patients and providers, while also driving significant cost efficiencies,” Chambers said in a prepared statement.
Endra Life Sciences said on Monday that it tapped Renaud Maloberti as its chief commercial officer.
Prior to joining Ann Arbor, Mich.-based company, Maloberti served as CCO at Bionik Laboraties and has held executive positions with FujiFilm SonoSite, BK Medical Systems, Draeger Medical Systems and GE Healthcare.
“I am thrilled to have Renaud join the Endra team. His deep commercial experience, particularly with breakthrough ultrasound devices, combined with his bi-cultural background and extensive clinical network, are a great fit for Endra’s TAEUS commercialization plans in Europe this year, and the U.S in 2020. Additionally, Renaud has demonstrated his impact in both large matrix organizations like GE Healthcare, and fast paced and lean microcap companies. It’s a rare combination that we believe will not only solidify our core management team, but also prepare the company to commercialize and scale our TAEUS technology in the years to come,” CEO Francois Michelon said in a prepared statement.
“I am very excited to join Endra, an innovative company with a game changing technology that addresses a large unmet clinical need in liver disease. I look forward to working with Francois and the team and leveraging my experience and clinical relationships to drive Endra’s commercialization success,” Maloberti said in a prepared release.
Dynatronics said late last month that it promoted current therapy products division prez Brian Baker to the position of chief operating officer.
Prior to joining the Salt Lake City, Utah-based company, Baker served as global operations VP at SeaSpine Holdings and as operations VP for the SeaSpine biz within Integra Lifesciences.